Daniel C. Cho

3.3k citations

61 papers · 1.7k indexed · 1 hit paper · h-index 21

Impact in

Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
Cancer Research top 5%
- Cancer Genomics and Diagnostics

Papers in ⓘ

Oncology 41
- Cancer Immunotherapy and Biomarkers 28
- CAR-T cell therapy research 9
Pulmonary and Respiratory Medicine 32
- Renal cell carcinoma treatment 28

Co-authors: Michael B. Atkins (17 shared papers)David F. McDermott (20 shared papers)Chiara Battelli (1 shared paper)James W. Mier (9 shared papers)Toni K. Choueiri (11 shared papers)David J. Panka (4 shared papers)Igor Puzanov (9 shared papers)Sabina Signoretti (2 shared papers)
Journals: Journal of Clinical Oncology (29 papers)Clinical Cancer Research (3 papers)Cancer (2 papers)Investigational New Drugs (2 papers)Molecular Cancer Therapeutics (2 papers)
Partner nations: United States United Kingdom Spain

In The Last Decade

Daniel C. Cho

61 papers receiving 1.7k citations

Hit Papers

align trajectories log scale

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial 2018 · 274 citations

Peers

Countries citing papers authored by Daniel C. Cho

Since Specialization

Citations

This map shows the geographic impact of Daniel C. Cho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel C. Cho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel C. Cho more than expected).

Fields of papers citing papers by Daniel C. Cho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel C. Cho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel C. Cho. The network helps show where Daniel C. Cho may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel C. Cho, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel C. Cho Line = papers co-authored together Daniel C. Cho links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 61 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial The Lancet Oncology ·Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, Mayer Fishman, David F. McDermott, Daniel C. Cho, Ulka N. Vaishampayan, Saby George, Thomas Olencki, Jamal Tarazi, Brad Rosbrook, Kathrine C. Fernandez, Mariajosé Lechuga, Toni K. Choueiri Hit paper breakdown →	2018	274
2	The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma Clinical Cancer Research ·Daniel C. Cho, Matthew B. Cohen, David J. Panka, Michael P. Collins, Musie Ghebremichael, Michael B. Atkins, Sabina Signoretti, James W. Mier	2010	154
3	A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors. Journal of Clinical Oncology ·Howard A. Burris, Manish R. Patel, Daniel C. Cho, Jeffrey Clarke, Martin Gutierrez, Tal Zaks, Joshua P. Frederick, Kristen Hopson, Kinjal Mody, Alverina Binanti-Berube, Céline Robert-Tissot, Bree Goldstein, Ben Breton, Jing Sun, Shan Zhong, Scott K. Pruitt, Karen Keating, Robert Meehan, Justin F. Gainor	2019	111
4	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma Journal of Clinical Oncology ·David F. McDermott, Jae‐Lyun Lee, Georg A. Bjarnason, James Larkin, Rustem Gafanov, Mark D. Kochenderfer, Niels Viggo Jensen, Frede Donskov, Jahangeer Malik, Alexandr Poprach, Scott S. Tykodi, Teresa Alonso‐Gordoa, Daniel C. Cho, Poul Geertsen, Miguel Á. Climent Durán, Christopher DiSimone, Rachel Kloss Silverman, Rodolfo F. Perini, Charles Schloss, Michael B. Atkins	2021	90
5	mTOR inhibitors in renal cell carcinoma Therapy ·Chiara Battelli, Daniel C. Cho	2011	89
6	Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology ·Daniel C. Cho, Jeffrey A. Sosman, Mario Sznol, Michael S. Gordon, Antoine Hollebecque, Omid Hamid, David F. McDermott, Jean‐Pierre Delord, Ina Rhee, Ahmad Mokatrin, Marcin Kowanetz, Roel Funke, Gregg Fine, Thomas Powles	2013	84
7	Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome European Journal of Cancer ·Donnette Dabydeen, Jyothi P. Jagannathan, Nikhil H. Ramaiya, Katherine M. Krajewski, Fabio A. Schutz, Daniel C. Cho, Iván Pedrosa, Toni K. Choueiri	2012	76
8	Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy British Journal of Urology ·Toni K. Choueiri, Meredith M. Regan, Jonathan E. Rosenberg, William Oh, Jessica Clément, Angela Amato, David F. McDermott, Daniel C. Cho, Michael B. Atkins, Sabina Signoretti	2010	71
9	First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors Journal for ImmunoTherapy of Cancer ·Elizabeth J. Davis, Juan Martín-Liberal, Rebecca Kristeleit, Daniel C. Cho, Sarah P. Blagden, Dominik Berthold, Dana B. Cardin, María Vieito, Rowan Miller, Prashanth Hari Dass, Angela Orcurto, Kristen Spencer, John E. Janik, Jason A. Clark, Thomas Condamine, Jennifer Pulini, Xuejun Chen, Janice M. Mehnert	2022	48
10	GSK-3β Inhibition Enhances Sorafenib-induced Apoptosis in Melanoma Cell Lines Journal of Biological Chemistry ·David J. Panka, Daniel C. Cho, Michael B. Atkins, James W. Mier	2007	45
11	NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT. Journal of Clinical Oncology ·Adi Diab, Michael E. Hurwitz, Daniel C. Cho, Vassiliki A. Papadimitrakopoulou, Brendan D. Curti, Scott S. Tykodi, Igor Puzanov, Nuhad K. Ibrahim, Sara M. Tolaney, Debu Tripathy, Jianjun Gao, Arlene O. Siefker‐Radtke, Wendy Clemens, Mary Tagliaferri, Scott Gettinger, Harriet M. Kluger, James Larkin, Giovanni Grignani, Mario Sznol, Nizar M. Tannir	2018	40
12	Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor‐targeted therapy Cancer ·Daniel C. Cho, Thomas E. Hutson, Wolfram E. Samlowski, Peter Sportelli, Brad Somer, Paul Richards, Jeffrey A. Sosman, Igor Puzanov, M. Dror Michaelson, Keith T. Flaherty, Robert A. Figlin, Nicholas J. Vogelzang	2012	36
13	Retrospective Analysis of the Safety and Efficacy of Interleukin-2 After Prior VEGF-targeted Therapy in Patients With Advanced Renal Cell Carcinoma Journal of Immunotherapy ·Daniel C. Cho, Igor Puzanov, Meredith M. Regan, Talya Schwarzberg, Virginia Seery, Mee-Young Lee, Vivian Liu, Rupal S. Bhatt, Henry Koon, James W. Mier, Jeffrey A. Sosman, Michael B. Atkins, David F. McDermott	2009	35
14	First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial. Journal of Clinical Oncology ·Toni K. Choueiri, James Larkin, Mototsugu Oya, Fiona Thistlethwaite, Marcella Martignoni, Paul Nathan, Thomas Powles, David F. McDermott, Paul B. Robbins, David D. Chism, Daniel C. Cho, Michael B. Atkins, Michael S. Gordon, Sumati Gupta, Hirotsugu Uemura, Yoshihiko Tomita, Anna Compagnoni, Alessandra di Pietro, Brian I. Rini	2017	32
15	Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920 Cancer ·Hamid Emamekhoo, Mark R. Olsen, Bradley Curtis Carthon, Alexandra Drakaki, Ivor Percent, Ana M. Molina, Daniel C. Cho, Johanna C. Bendell, Lucio Gordan, Arash Rezazadeh Kalebasty, Daniel J. George, Thomas E. Hutson, Edward Arrowsmith, Joshua Zhang, Jesús Zoco, Jennifer L. Johansen, David Leung, Scott S. Tykodi	2021	31
16	Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC). Journal of Clinical Oncology ·Daniel C. Cho, Amit Mahipal, Afshin Dowlati, Warren Chow, Neil H. Segal, Ki Y. Chung, Bryan J. Schneider, John Nemunaitis, Albiruni Ryan Abdul Razak, Frank Tsai, Ani Sarkis Balmanoukian, Lyudmila Bazhenova, Feng Xiao, Natasha Angra, Shaad E. Abdullah, Jason J. Luke	2018	29
17	Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920. Journal of Clinical Oncology ·Hamid Emamekhoo, Mark R. Olsen, Bradley Curtis Carthon, Alexandra Drakaki, Ivor Percent, Ana M. Molina, Daniel C. Cho, Johanna C. Bendell, Lucio Gordan, Arash Rezazadeh Kalebasty, Daniel J. George, Thomas E. Hutson, Richard J. Lee, Tina C. Young, Jennifer L. Johansen, Scott S. Tykodi	2019	27
18	Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib. Journal of Clinical Oncology ·A. B. Ackerman, David F. McDermott, Donald P. Lawrence, Anasuya Gunturi, Keith T. Flaherty, Anita Giobbie‐Hurder, F. Stephen Hodi, Nageatte Ibrahim, Michael B. Atkins, Daniel C. Cho, Ryan J. Sullivan	2012	26
19	A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors Investigational New Drugs ·Geoffrey I. Shapiro, Patricia LoRusso, Daniel C. Cho, Luna Musib, Yibing Yan, Matthew Wongchenko, Ilsung Chang, Premal H. Patel, Iris T. Chan, Sandra Sanabria Bohórquez, Raymond D. Meng, Johanna C. Bendell	2020	23
20	Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors Clinical Cancer Research ·Vandana G. Abramson, Jeffrey G. Supko, Tarah J. Ballinger, James M. Cleary, John Hilton, Sara M. Tolaney, Nicole G. Chau, Daniel C. Cho, Joseph Pearlberg, Joanne Lager, Geoffrey I. Shapiro, Carlos L. Arteaga	2016	23

About Daniel C. Cho

Daniel C. Cho is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research and Immunology, having authored 61 papers that have together received 1.7k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (28 papers), Cancer Immunotherapy and Biomarkers (28 papers), Renal and related cancers (9 papers), CAR-T cell therapy research (9 papers), Cancer Genomics and Diagnostics (9 papers), PI3K/AKT/mTOR signaling in cancer (8 papers), Immunotherapy and Immune Responses (6 papers) and Melanoma and MAPK Pathways (4 papers). The work is most often cited by research in Oncology (881 citations), Cancer Research (381 citations), Pulmonary and Respiratory Medicine (805 citations), Immunology (336 citations) and Molecular Biology (851 citations). Daniel C. Cho has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Michael B. Atkins, David F. McDermott, Chiara Battelli, James W. Mier, Toni K. Choueiri, David J. Panka, Igor Puzanov, Sabina Signoretti, Mayer Fishman and Jamal Tarazi. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Cancer, Investigational New Drugs and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact